Check out our most popular compounded medications! Get Started
The Squaric Acid Dibutylester 2% Topical Liquid is a specially compounded preparation intended for external use on the skin or mucosal surfaces. This formulation is designed to deliver a precise concentration of squaric acid dibutylester, a contact sensitizer, directly to the affected area for therapeutic effect. The liquid dosage form ensures ease of application and allows for the treatment to be localized, minimizing systemic absorption and potential side effects.
This topical liquid is primarily used in the treatment of warts, including those caused by human papillomavirus (HPV), and for alopecia areata, an autoimmune condition resulting in hair loss. The medication works by inducing a local immune response, which in turn helps to eliminate the targeted lesions or stimulate hair growth. Due to its mechanism of action, squaric acid dibutylester is also utilized for dermatological immunotherapy in patients with these disease states.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Squaric Acid Dibutylester (SADBE) 2% Topical Liquid is a specialized dermatological compound that is meticulously prepared for direct application to the skin or mucosal surfaces. This bespoke liquid formulation is designed to deliver a precise concentration of the active ingredient, Squaric Acid Dibutylester, for the treatment of various dermatological conditions. The 2% concentration has been selected to optimize therapeutic efficacy while minimizing potential side effects.
The primary use of SADBE is in the treatment of warts, including those that are recalcitrant to other forms of therapy. It functions as a topical immunotherapy agent, leveraging the body's immune response to target the human papillomavirus (HPV) that causes warts. By applying SADBE to the affected area, it acts as a contact sensitizer, helping the immune system recognize and destroy the wart tissue. Additionally, SADBE has been utilized in the treatment of alopecia areata, an autoimmune condition resulting in hair loss. The compound stimulates a local immune response that can alter the course of the disease, promoting hair regrowth.
For patients and prescribers considering the use of Squaric Acid Dibutylester 2% Topical Liquid, it is important to understand that the treatment is typically part of a longer-term therapeutic strategy. The application schedule and duration of treatment may vary based on the individual patient's response and the specific condition being treated. It is also crucial to apply the medication precisely as directed to the affected area to avoid unnecessary exposure to surrounding healthy skin.
As with any medication, there are potential side effects associated with SADBE, including local skin reactions such as redness, itching, and blistering at the site of application. These reactions are generally mild and indicative of the desired immunological response. However, patients should be monitored for any signs of severe or unexpected adverse effects. It is also important to note that SADBE should be used with caution in patients with a known hypersensitivity to the compound or any of the formulation's excipients.
Bayview Pharmacy's team of compounding pharmacists is dedicated to providing high-quality, patient-specific formulations. We are available to answer any questions and provide additional information to both patients and prescribers regarding the use of Squaric Acid Dibutylester 2% Topical Liquid. Please do not hesitate to reach out to us for guidance or to discuss the suitability of this formulation for your patients.
Squaric Acid Dibutylester (SADBE) is a topical immunotherapy agent primarily used for treating alopecia areata and warts by inducing a local allergic reaction to stimulate the immune system. As a compounding pharmacy, we have prepared a 2% topical liquid formulation of SADBE for direct application to the skin or mucosal surfaces. It is important to consider potential drug interactions when using this medication, although due to its localized action, systemic interactions are less common compared to oral medications.
When using SADBE, it is crucial to avoid concurrent use of topical corticosteroids on the same treatment areas, as they may diminish the immunotherapeutic effect of SADBE by suppressing the local immune response it is intended to provoke. Patients should also be cautious when using other topical agents that could potentially cause skin irritation or alter skin barrier function, such as retinoids, keratolytics, or strong cleansers, as these may exacerbate irritation or alter the efficacy of SADBE.
While systemic absorption of SADBE is minimal, it is still advisable to monitor for potential interactions with systemic immunosuppressive agents, such as cyclosporine, methotrexate, or biologic therapies. These medications could potentially reduce the effectiveness of SADBE by suppressing the immune response it aims to activate. Conversely, if a patient is receiving desensitization therapy for allergies, the use of SADBE may interfere with the intended immune modulation of such treatments.
Photosensitizing agents, whether topical or systemic, may also interact with SADBE. Patients should be advised to protect the treated areas from excessive sunlight or artificial UV radiation, as SADBE can cause photosensitivity, increasing the risk of sunburn or photoallergic reactions when used in conjunction with such agents.
It is also important to consider the potential for interactions with cosmetics, sunscreens, and other personal care products applied to the treatment area. These products may contain ingredients that could either reduce the efficacy of SADBE or increase the risk of local irritation. Patients should be instructed to discuss the use of any such products with their healthcare provider before starting treatment with SADBE.
As with any medication, it is essential to provide a complete medical history, including all over-the-counter medications, herbal supplements, and topical treatments, to the healthcare provider before starting SADBE therapy. This will help identify any potential interactions and ensure the safe and appropriate use of the medication.
If you have any questions or concerns regarding the use of Squaric Acid Dibutylester 2% Topical Liquid or potential drug interactions, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to provide guidance and support to both patients and prescribers.
Squaric Acid Dibutylester (SADBE) 2% Topical Liquid is a specially compounded medication that is applied directly to the skin or mucosal surfaces. This formulation is designed to elicit an immunotherapy response, primarily used in the treatment of warts and alopecia areata, which are skin conditions caused by an abnormal immune response. The active ingredient, Squaric Acid Dibutylester, is a contact sensitizer that works by modulating the immune system. When applied to the affected area, SADBE helps to redirect the immune system's attention to the site of application, thereby stimulating a localized allergic reaction. This controlled reaction is intended to prompt the body to attack the virus causing warts or to stimulate hair growth in areas affected by alopecia areata.
The mechanism of action of SADBE involves the activation of the body's T-lymphocytes, a type of white blood cell that plays a critical role in the immune response. By applying SADBE to the skin, the body recognizes the compound as a foreign substance, which triggers an immune response. This response includes the release of cytokines and other inflammatory mediators that lead to an allergic reaction. In the case of warts, this immune response can result in the destruction of human papillomavirus (HPV)-infected cells. For alopecia areata, the immune system's redirected focus can reduce the misguided attack on hair follicles, potentially leading to hair regrowth.
It is important for patients and prescribers to understand that the use of SADBE is a form of immunotherapy and may take several weeks or months to show effectiveness. The treatment regimen typically involves an initial sensitization phase, followed by periodic applications to maintain the immune response. The concentration of SADBE and the frequency of application may be adjusted based on the patient's response and tolerance to the treatment. As with any medication, there are potential side effects, including local skin reactions such as redness, itching, and blistering at the site of application. These reactions are generally mild and indicate that the medication is working as intended.
For optimal results, it is crucial to follow the specific instructions provided by the compounding pharmacist and the prescribing physician. The formulation should be applied carefully to the affected area, avoiding contact with healthy skin to minimize irritation. Patients should also be advised to report any severe or unexpected reactions to their healthcare provider.
At Bayview Pharmacy, we are committed to providing high-quality, customized medications to meet the unique needs of each patient. If you have any questions about Squaric Acid Dibutylester 2% Topical Liquid or its use in treating warts and alopecia areata, please do not hesitate to reach out to us. Our knowledgeable team of compounding pharmacists is here to support both patients and prescribers with the information and guidance needed to effectively manage these conditions.
Squaric Acid Dibutylester 2% Topical Liquid is a treatment specifically designed to be applied directly to the skin, and is typically used for treating dermatological conditions such as warts or alopecia areata by inducing a localized allergic reaction that helps to recruit the immune system to the affected area.
The liquid should be applied directly to the affected area of skin with care, using an applicator or a gloved hand if directed by your physician. Apply only the recommended amount and avoid spreading to unaffected skin or mucous membranes.
It is important to discuss with your healthcare provider before using Squaric Acid Dibutylester 2% Topical Liquid if you are pregnant, planning to become pregnant, or are breastfeeding to ensure the safety of you and your baby.
Common side effects include localized itching, redness, or inflammation at the site of application. More serious side effects are rare but may include blistering or severe dermatitis. If any side effects become troublesome or severe, contact your healthcare provider.
Response times can vary depending on the individual and the condition being treated. Some patients may see results within a few weeks, whereas others may require longer treatment periods. It's important to follow your healthcare provider’s guidance and continue treatment as prescribed.
You should follow your healthcare provider's advice on covering the treated area. Some conditions may benefit from occlusion with a bandage, while others should be left uncovered to ensure the solution dries properly and to prevent spreading of the liquid.
There are no specific instructions to avoid sunlight while using this medication unless otherwise advised by your healthcare provider. However, it is generally sensible to protect sensitive treated skin areas from excessive sun exposure.
If accidental contact occurs with healthy skin, wash the area thoroughly with soap and water. Contact your healthcare provider if you notice any adverse reactions on the unaffected skin.
Store the liquid at room temperature away from light and moisture. Keep the bottle tightly closed and out of reach of children and pets.
If you miss an application, apply it as soon as you remember. If it is nearly time for your next scheduled application, skip the missed dose and apply the next dose at the regular time. Do not double up to make up for a missed dose without consulting your healthcare provider.
Use of Squaric Acid Dibutylester 2% Topical Liquid in children should only be under the direct guidance of a healthcare provider, as the safety and effectiveness of this medication in pediatric patients may differ from adults.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
